

Platelet mapping

Intended use: Assessment of **AA [Arachidonic acid- Aspirin]** and **ADP [Adenosine 5 phosphate- Plavix]**





TEG[®]6s PlateletMapping[®] Interpretation Guide

The PlateletMapping assay specifically determines the MA (Maximum Amplitude, a measure of clot strength) and the reduction in MA due to genetics, surgical procedures and/or antiplatelet therapy.

Platelet receptor function is assessed relative to the baseline clot strength (HKH-MA) and fibrin only (ActF-MA) clot strength.

Inhibition is calculated automatically by comparing the MAs of the agonist (AA & ADP) with that of the baseline platelet and fibrin contribution.

The analyzer reports the inhibition of MA as a percentage of reduction in clot strength.

	Clot Strength Baseline - Plt & Fib	Clot Strength Fibrin Only	Clot Strength AA Receptor Action	Clot Strength ADP Receptor Action
Test - Parameter	HKH - MA	ActF - MA	AA - MA	ADP - MA
Reagent	Kaolin Heparinase	Activator F	Activator F + AA	Activator F + ADP
Hemostatic Activity	Thrombin overrides the inhibitory effects of receptor specific inhibition. Provides baseline clot strength.	Activator F replaces thrombin's role in the conversion of fibrinogen to fibrin and FXIII's role in cross-linking.	Clot strength in addition to ActF-MA is due to platelet-fibrin bonding related to AA.	Clot strength in addition to ActF-MA is due to platelet-fibrin bonding related to ADP.
Normal Tracings				
Shaded Reference Ranges for illustration only				
Reference Ranges	MA 53-68 mm	MA 2-19 mm	MA 51-71 mm	MA 45-69 mm


Results from the TEG 6s analyzer should not be the sole basis for a patient diagnosis, but should be evaluated together with the patient's medical history, the clinical picture and, if necessary, other coagulation tests.



TEG[®]6s PlateletMapping[®] Interpretation Guide

Platelet receptor response to the Platelet agonists AA & ADP is relative to baseline platelet and fibrin function.

In general terms, the closer the ADP or AA response is to the fibrin only (no platelet) result the more inhibited that receptor is.



For a list of worldwide office locations and contact information, visit www.haemonetics.com/office/location

© 2017 Haemonetics Corporation. Haemonetics and TEG are registered trademarks of Haemonetics Corporation in the USA, other countries or both. PlateletMapping is a registered trademark of Cora Healthcare, Inc. 02.2017 USA TRN-016-100065-US(A4)



